The digital health fundraising market seems to be truly normalizing following the highs and lows of the pandemic, according to market research. During the first half of this year, U.S. digital health startups raked in $5.7 billion across 266 deals.
Revolution Medicines drug RMC-6236 increased progression-free survival in patients with advanced cases of pancreatic ductal adenocarcinoma. With these results, the biotech is preparing for a Phase 3 clinical trial in this indication, the most common type of pancreatic cancer.
Cost reduction is no longer a top priority for healthcare finance leaders, a new Deloitte survey found. In past years, cost reduction was among the top three priorities.
Human Factors and Ergonomics (HF/E) play a major role, acting as a bridge between the human element and the healthcare system. Creating a work environment where human potential flourishes, and where technology serves as a seamless extension of our ability to care.
In this episode, we talk about hospital consolidation and recent Supreme Court decisions affecting healthcare. Companies and organizations mentioned in this episode are Risant Health, Kaiser Permanenete, Cone Health, Geisinger, General Catalyst, Summa Health, FDA, the Supreme Court.
No comments